Vernalis Share Discussion Threads

[fhmktg] 06/7/2007 16:21

Blooming 'eck; somebody has deep pockets. Must be a willing seller not to move the price?

The bigger volumes featured earlier as cross trades?

[master rsi] 06/7/2007 15:47

Plenty of volume/ large trades again today and yet no movement

[iancath] 04/7/2007 08:14

Just look at the volume graph. Exciting times ahead.

[fhmktg] 03/7/2007 15:49

And more today.
Gearing up for Frova decision in August?
Could be the Williams sister's performance yesterday - she is the front for the advertising campaign for PM migraine use for Frova after all!

[iancath] 02/7/2007 17:37

Another 1.2 million today.

[iancath] 28/6/2007 18:17

2.8 million buys today. Most unusual.

[iancath] 28/6/2007 13:44

Well it's not quiet this morning, 1.5 million shares bought.
Didn't think there was anything in the immediate pipeline, anyone heard anything?

[maysun] 21/6/2007 11:47

Not only here, the whole market is dead quiet.......LOL!!!

Company is making steady progress, so its just a matter of time it will go up........LOL!!!!

[iancath] 21/6/2007 08:54

Thanks for that, it's been rather quiet here lately but the next few months are going to be interesting to say the least!

[maysun] 21/6/2007 07:53

Webcast now available:

[master rsi] 11/6/2007 14:11

Howls

I hope you do not mind, but I copied and pasted the article below, it says BUY up to 88p.....

From Market Insider.

Vernalis
June 11th, 2007
Phase III data presented to the American Headache Society meeting over the weekend goes down well will Bridgwell, which rates the stock a buy up to 88p.
Broker adds: 'This additional trial data has been submitted to the FDA in the form of a supplemental New Drug Application (sNDA), to support the earlier efficacy and safety data filed in September 2006. Given the solid nature of the data filed to date, we expect the FDA to approve frovatriptan for short-term prevention of menstrually related migraine, by 19th August 2007 (PDUFA date).
'The additional data filed today should further support a positive decision by the FDA and help position the product more firmly once it reaches market.'

[fhmktg] 11/6/2007 08:45

Good to see the data.

Endo & Vernalis must be feeling confident the FDA process is going OK, for a positive approval in August.
This should get some useful press coverage in the USA.

Miss Williams will be getting her makeover, ready for her role as the face of Frova!

[iancath] 11/6/2007 07:49

11 June 2007


VERNALIS PLC ANNOUNCES PHASE III STUDY DATA THAT DEMONSTRATES SHORT TERM
PREVENTION TREATMENT WITH FROVA(R) REDUCES FREQUENCY AND SEVERITY OF MENSTRUAL
MIGRAINE

WINNERSH, U.K., 11 June, 2007 -- Vernalis plc (LSE: VER) is pleased to reproduce
below the announcement made by Endo Pharmaceuticals Inc; in respect of the
presentation of data on Frova(R) at the American Headache Society.


FROVA (R) Phase III Study Data Demonstrates That Short-Term Prevention Treatment
Reduces Frequency and Severity of Menstrual Migraine


CHICAGO, IL, Jun 09, 2007 (MARKET WIRE via COMTEX News Network) -- Endo
Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings
Inc. (NASDAQ: ENDP), has presented results from a Phase III randomized,
double-blind, placebo-controlled clinical trial evaluating FROVA (frovatriptan
succinate) 2.5 mg tablets as a six-day preventative treatment in women with
difficult-to-treat menstrual migraine (MM). The data demonstrated that FROVA
significantly reduced the frequency and severity of MM as well as the
disabilities related to them. The results, which were presented here today at
the annual meeting of the American Headache Society (AHS), were from the second
of the two successful Phase III placebo-controlled clinical trials evaluating
the efficacy and safety of FROVA in MM prophylaxis.

Women receiving FROVA started the six-day regimen two days prior to the onset of
their anticipated headache. Starting treatment two days before the expected
headache ensures that patients have adequate blood levels at the time they
usually start to experience MM, and continuing treatment for six days ensures
that they are covered during the whole period when they are likely to experience
those headaches. Women in the study had responded poorly to previous acute
triptan treatment for MM.

"In this study, appropriately timed short-term treatment with FROVA prevented or
significantly reduced the pain of difficult-to-treat but often predictable
migraines associated with the menstrual period," said the lead investigator in
the trial, Jan Lewis Brandes, M.D., of the Nashville Neuroscience Group and
assistant clinical professor of the Department of Neurology at Vanderbilt
University School of Medicine. "This is exciting news for women and their
physicians who need to realize that the debilitating pain of menstrual migraine
is not inevitable and is not a normal part of their menstrual cycle."

"In patients with menstrual migraine and predictable menses, I am intrigued by
the potential for a short-term prevention treatment to prevent or minimize MM
symptoms without continuously exposing patients to a drug," said Stephen
Silberstein, M.D., professor of neurology at the Jefferson Medical College of
Thomas Jefferson University, director of the Jefferson Headache Center and lead
investigator of the initial efficacy study of FROVA for the short-term
prevention of menstrual migraine.

Study Results

In the trial, the MM status of study participants was confirmed during a
placebo-controlled, single-blind, run-in phase. Women were randomized in the
double-blind study to receive FROVA 2.5 mg once a day, FROVA 2.5 mg twice a day,
or placebo (ratio 3:2:3).

FROVA once or twice daily significantly improved the number of headache-free
perimenstrual periods (PMPs) compared to women who received placebo. FROVA also
significantly reduced the incidence of severe migraines and therefore tended to
improve the ratio of severe to mild headache compared to women who received
placebo. Efficacy data were collected from 410 women in North America and
Europe, 85 percent of whom participated in the study over three PMPs. Efficacy
data were collected from 410 women in North America and Europe, 85 percent of
whom participated in the study over three PMPs.

The study's primary endpoint was the number of completely headache-free PMPs.
FROVA therapy significantly improved the number of headache-free PMPs per
patient (0.92 (twice daily), p < 0.0001; 0.69 (once daily), p=0.009) versus 0.42
(placebo). The incidence of severe headache was significantly less with FROVA
once daily (44 percent; p=0.007) and twice daily (40 percent; p=0.0003) compared
with placebo (58 percent), lowering the ratio of severe to mild migraine from
11:1 with placebo to 4:1 (once daily) and 2:1 (twice daily) with FROVA.

Reductions in migraine symptoms were significant for nausea (twice daily only),
photophobia, and phonophobia (p < 0.008; BID and QD vs. placebo), and patients
experienced significantly less functional impairment during treatment with FROVA
(p < 0.0001; QD and BID vs. placebo).

Both FROVA regimens were equally well tolerated with a low rate of adverse
events. The most commonly reported adverse events were upper respiratory tract
infection (37 patients), nausea (36 patients), and dizziness (31 patients). Most
adverse events were rated mild or moderate in severity and did not increase in
severity with increasing doses of FROVA; the percentage rated severe was 19
percent in the placebo group and 22 percent (once daily) and 14 percent (twice
daily) in the FROVA groups.

Endo has submitted a supplemental New Drug Application (sNDA) for FROVA 2.5 mg
tablets for the short-term (six days per month) prevention of MM to the U.S.
Food and Drug Administration (FDA).

[master rsi] 05/6/2007 19:01

From the "UPS" thread ............

VER 64 - 64.75p +2.675p
A late mover today after being selected yesterday reached 66.50p at one time
Volume cameback up to 478K as it was moving higher

[master rsi] 05/6/2007 15:24

It took its time but now is 63 -63.25p +1.50p on a bad market day, a bit more volume than lately 159K so far

[master rsi] 04/6/2007 16:12

Not much going on yet apart that the order book keeps taking in small trades "AT" @ 62p, from the 16K it was earlier on the offer side

Tomorrow the 62p will not be there for sure but just now one can buy at 61.75p

[master rsi] 04/6/2007 15:45

And that is the news not so long ago..........

Vernalis plc
Director's Share Dealing

WINNERSH, U.K 4th June 2007 -- Vernalis plc (LSE: VER) ("Vernalis" or the
"Company") announces that it was informed today that George Kennedy,
Non-Executive Director of the Company, today bought 30,000 Ordinary Shares of 5
pence each at a price of 61.75 pence per share.

Following this purchase of shares, Mr Kennedy is the beneficial owner of 79,094
Ordinary Shares, representing 0.025% of the Company's current issued share
capital.

[master rsi] 04/6/2007 15:42

Director buys 30K at 61.75p today

[maysun] 17/5/2007 09:35

A lot of larger buys in past weeks, someone are accumulating slowly and quietly. This one will top 100p as soon as Frova approval is reached...............LOL!!!!

[master rsi] 17/5/2007 08:04

Another collaboration on the bag, with upfront payment ........


Vernalis, France's Servier sign cancer drug discovery pact; terms undisclosed

LONDON (Thomson Financial) - Vernalis PLC and Servier Research Group,
France's largest privately-owned pharmaceutical company, have entered into a
joint, three-year, cancer drug discovery collaboration.
The collaboration will use Vernalis' proprietary drug discovery platform on
an undisclosed cancer target.
The British company will receive an up front payment and a share in the
downstream success of the product. Terms were not disclosed.
Vernalis shares closed Wednesday at 66.5 pence, valuing the company at
208.35 mln stg.

[iancath] 17/5/2007 07:59

There's certainly plenty in the pipeline. Fingers crossed for Frova.

[fhmktg] 17/5/2007 07:57

19th August for Frovan update - optimistic RNS this morning